Back to Market返回行情

NVS Novartis AG

USHealthcare
$153.76+0.67%ClosedMarket Cap: $293.38B

As of 2026-07-17

Why NVS matters now

Novartis AG (NVS) is a US stock in Healthcare. The latest InvestLog snapshot shows $153.76 with +0.67% on the session and $293.38B in market capitalization; recent performance reads 1-month -2.23% and YTD +6.68%.

The latest financial table shown here is Q1 2026, with revenue of $13.52B, net income of $3.16B, and EPS of $1.65. Investors can compare that operating picture with valuation signals such as P/E 21.32 and FCF yield 5.9%.

InvestLog's latest related AI research is a Pre-Earnings Setup note titled "NVS pre-earnings setup: report due 2026-07-21". The latest indexable market news headline is "Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Hold with a median target of $170.00. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

21.32

PEG

1.25

P/B

7.25

P/S

5.05

EV/EBITDA

14.37

DCF Value

$276.78

FCF Yield

5.9%

Div Yield

3.1%

Margins & Returns

Gross Margin

75.1%

Operating Margin

29.9%

Net Margin

24.3%

ROE

31.5%

ROA

11.3%

ROIC

14.9%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$13.52B$3.16B$1.65
Q4 2025$13.33B$2.41B$1.25
FY 2025$54.81B$14.06B$7.19
Q3 2025$14.36B$3.93B$2.02

Analyst Ratings

Consensus

Hold

Target (Consensus)

$170.00

Target (Median)

$170.00

Target Range

$170.00 - $170.00

Strong Buy: 3Buy: 2Hold: 5Sell: 2Strong Sell: 0
Morgan StanleyOverweight
2026-03-26
BarclaysEqual Weight
2026-01-06
JP MorganOverweight
2025-12-08
Goldman SachsSell
2025-09-12

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

CH

Exchange

Beta

0.49

Novartis AG is a global healthcare enterprise dedicated to the discovery, development, production, and distribution of medical products across the world. The company operates through two main divisions: Innovative Medicines and Sandoz. Its Innovative Medicines segment provides prescription drugs to both patients and healthcare professionals, addressing a wide array of therapeutic areas such as ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory health, cardiovascular conditions, renal disorders, and metabolic diseases. The Sandoz division is responsible for the formulation, manufacturing, and commercialization of finished dosage form medicines. It also supplies active pharmaceutical ingredients and completed small molecule pharmaceuticals to other entities, in addition to offering retail generic drugs and anti-infectives. Furthermore, Sandoz provides crucial pharmaceutical intermediates and active ingredients, predominantly antibiotics, as well as protein- and biotechnology-derived products, including biosimilars, and offers biotechnology manufacturing services. Novartis AG also engages in strategic alliances, notably a licensing and collaboration deal with Alnylam Pharmaceuticals for the development, production, and marketing of inclisiran. Additionally, it holds a clinical partnership with Kura Oncology, Inc. to assess the combined efficacy of Tipifarnib and Alpelisib in patients diagnosed with head and neck squamous cell carcinoma. Founded in 1996, the company is headquartered in Basel, Switzerland.